Previous 10 | Next 10 |
Shares of the off-the-shelf cell therapy company Allogene Therapeutics (NASDAQ: ALLO) are ending the week on a sour note. The biotech's stock is down by a jaw-dropping 44% as of 11:36 a.m. EDT Friday morning. Allogene's shares are plunging today after the U.S. Food and Drug Admi...
Gainers: ChemoCentryx (NASDAQ:CCXI) +70%. Renren (NYSE:RENN) +48%. DatChat (NASDAQ:DATS) +32%. ReShape Lifesciences (NASDAQ:RSLS) +29%. Huadi International (NASDAQ:HUDI) +24%. Voyager (NASDAQ:VYGR) +22%. NextPlay Technologies (NASDAQ:NXTP) +21%. Tian Ruixiang (NASDAQ:TIRX) +20%. Lilium (NASDA...
Gainers: ChemoCentryx CCXI +57%, ReShape Lifesciences (NASDAQ:RSLS) +30%, Voyager Therapeutics VYGR +13%, Sundial Growers (NASDAQ:SNDL) +10%, Flora Growth (NASDAQ:FLGC) +6%. Losers: Allogene Therapeutics ALLO -42%, Cellectis CLLS -19%,...
Recording the biggest intraday loss in nearly six months, Intellia Therapeutics (NTLA -10.7%) has shed all the gains made since late June when the company and its partner Regeneron (NASDAQ:REGN) showed promising in-vivo CRISPR-based genome editing data for the first time in humans. The w...
Allogene Therapeutics (NASDAQ:ALLO) down nearly a third premarket after FDA placed clinical hold on its AlloCAR T trials yesterday. The Agency's decision was based after a chromosomal abnormality was reported in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study. Cellect...
On Thursday, Allogene Therapeutics Inc. ( NASDAQ:ALLO ) shares plummeted by more than 37% in the after-hours session after the US Food and Drug Administration (FDA) put on hold the clinical trial for AlloCAR T. The stock had surged 1.7% during the regular trading hours. Allo...
Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to Therapy Investigation Ongoing to Further Characterize the Finding, Including Any Clinical Relevance, Evidence o...
With a list of 62 recent IPOs making entry to the Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations, we discuss the recently-IPOd healthcare stocks joining the index. Following up on a previous article on biotech stocks in the group, in...
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Jae Park, M.D.,...
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participat...
Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) : Start-Up Activities Underway; Enrollment to Begin Mid-2024 Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Dat...